Papillary thyroid carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The most common RET fusions are CDCC6-RET and NCOA4-RET in PTC and KIF5B-RET in NSCLC.
|
31715421 |
2019 |
Papillary thyroid carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Two samples harboring RET/PTC1 and RET/PTC3 rearrangements were positive controls whereas the remaining ones were negative regarding the common PTC alterations.
|
30664823 |
2019 |
Papillary thyroid carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
MATERIAL AND METHODS Four cell lines included TPC-1 (BRAFWT/WT), BCPAP (BRAFV600E/V600E), PCCL3, and PTC3-5 (RET/PTC), were grown in culture in vitro with or without suppression of NF-κB using pyrrolidine dithiocarbamate (PDTC), and cell proliferation, and cell migration were evaluated.
|
29117154 |
2017 |
Papillary thyroid carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Six of 27 PTCs (22%) had ret proto-oncogene (RET) fusions (RET/PTC1, n = 5; RET/PTC3, n = 1); 2 tumors measured >2 cm and diffusely involved the thyroid, and 5 had lymphatic invasion, with vascular invasion in 2.
|
26784937 |
2016 |
Papillary thyroid carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Stratified analysis according to RET/PTC subtype and geographical area showed that this association was restricted to the RET/PTC3 subtype (OR = 8.30, 95%CI: 4.32-15.96, P < 0.001) in the Western population.
|
26918339 |
2016 |
Papillary thyroid carcinoma
|
0.400 |
FusionGene
|
disease |
ORPHANET |
Among 73 PTC patients with sufficient tissue available for FISH and multiplex qPCR, 10 cases were defined as RET/PTC positive by both assays, including eight CCDC6/RET and two NCOA4/RET fusions with relatively high RET mRNA.
|
25407564 |
2015 |
Papillary thyroid carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our results indicate that RET/PTC3 gene rearrangements are the most prevalent form of rearrangements in PTCs of Chennai population.
|
24957039 |
2014 |
Papillary thyroid carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Hence, our findings highly support the use of siRNA RET/PTC3-SQ NPs as a new promising treatment for patients affected by PTC expressing RET/PTC3.
|
24759995 |
2014 |
Papillary thyroid carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Nuclear receptor coactivator 4 (NcoA4), also known as androgen receptor-associated protein 70 (ARA70), was initially discovered as a component of Ret-Fused Gene expressed in a subset of papillary thyroid carcinomas.
|
22562579 |
2012 |
Papillary thyroid carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Twenty-five PTCs (11 with BRAF(V600E), 4 with RET/PTC1, and 10 without mutation in HRAS, KRAS, NRAS, BRAF, RET/PTC1, or RET/PTC3) were analyzed using Genome-Wide Human SNP Array 6.0 which allows us to detect copy number alteration (CNA) and uniparental disomy (UPD), also referred to as copy neutral loss of heterozygosity, in a single experiment.
|
22558328 |
2012 |
Papillary thyroid carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Influence of RET/PTC1 and RET/PTC3 oncoproteins in radiation-induced papillary thyroid carcinomas on amounts of cytoskeletal protein species.
|
20839015 |
2011 |
Papillary thyroid carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The BRAF(V600E) was found in 84/266 (31.6%) cases, RAS mutations in 11/266 (4.1%) and RET/PTC in 55/266 (20.7%; 42/266 (15.8%) RET/PTC1 and 13/266 (4.9%) RET/PTC3).
|
21498916 |
2011 |
Papillary thyroid carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Gene expression in RET/PTC3 and E7 transgenic mouse thyroids: RET/PTC3 but not E7 tumors are partial and transient models of human papillary thyroid cancers.
|
18583418 |
2008 |
Papillary thyroid carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Human rearranged RET/PTC3 (papillary thyroid carcinoma) proto-oncogene and high-risk human papillomavirus (HPV) type 16 E7 oncogene induces in the mouse a neoplastic transformation of thyroid follicular cells.
|
18985036 |
2008 |
Papillary thyroid carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
RET/PTC1 (two out of seven) and RET/PTC3 (one out of seven), which have been shown in large PTC series to comprise together more than 90% of RET/PTC types, were found in <50% of the cases investigated.
|
17464312 |
2007 |
Papillary thyroid carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
To evaluate BRAF(V600E) mutation on consecutive fine-needle aspiration biopsy (FNAB) specimens in order to assess FNAB's usefulness in preoperative papillary thyroid carcinoma (PTC) diagnosis with the contemporaneous analysis of RET/PTC1 and RET/PTC3 rearrangements obtained from ex vivo thyroid nodules.
|
17727338 |
2007 |
Papillary thyroid carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Rearrangements of the RET protooncogene (RET/PTC1, RET/PTC2 and RET/PTC3) were detected in 7 out of 33 PTC (21%), and rearrangements of NTRK1 [Trk-T1 and Trk(TPM3)] were detected in 4 out of 33 examined samples (12%).
|
16483615 |
2006 |
Papillary thyroid carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
RET gene rearrangements (RET/PTC1 and RET/PTC3) in papillary thyroid carcinomas from an iodine-rich country (Japan).
|
16015630 |
2005 |
Papillary thyroid carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In our study, RET/PTC1, RET/PTC2, and RET/PTC3 oncogenes were found in only 7 of 105 (7%) sporadic PTCs.
|
15876154 |
2005 |
Papillary thyroid carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Real-time quantitative RT-PCR identifies distinct c-RET, RET/PTC1 and RET/PTC3 expression patterns in papillary thyroid carcinoma.
|
15502856 |
2004 |
Papillary thyroid carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Ret/PTC-3 was detected in only follicular variant subtype (60%) and was not detected in classic PTC.
|
12574236 |
2003 |
Papillary thyroid carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Whereas the prevalences of RET/PTC1 and RET/PTC3 were almost equal in classic and follicular PTC, all of the TCV-positive cases expressed the RET/PTC3 rearrangement.
|
11786418 |
2002 |
Papillary thyroid carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The prevalence of RET/PTC activation in PTC is high and RET/PTC3 is the only type of activation identified in Hong Kong Chinese and is an important genetic event underlying the development of PTC in the population.
|
12457448 |
2002 |
Papillary thyroid carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Using the RT-PCR technique, we observed a RET/PTC rearrangement in the carcinomatous areas of patients of both families: PTC1 in family 1 and PTC3 in family 2 and a RET/PTC rearrangement in non-malignant thyroid tissue with LT in family 2.
|
11747322 |
2001 |
Papillary thyroid carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
More than 90% of PTC with RET rearrangement exhibit a PTC1 or PTC3 type of rearrangement with an inversion of the H4 or ELE1 gene, respectively, on chromosome 10.
|
11318605 |
2001 |